Fate Therapeutics Q2 2023: cash $385M, FT522 Phase 1 start-up, FT825 IND planned 2H23

FATE THERAPEUTICS INC

2023-Q2 EPS reported -$0.73 revenue$59,913,000

Cash position $385.2M as of June 30, 2023; runway into 2H25.
Q2 2023 revenue $0.9M from ONO collaboration; GAAP op ex $63.5M incl $12.9M stock comp.
Phase 1 start-up for FT522 ADR-armed CAR NK program; IND allowed May 2023.
IND submission planned 2H23 for FT825/ONO-8250 HER2-targeted CAR T program under ONO collaboration.
FT576 BCMA-targeted CAR NK and FT819 CD19-targeted CAR T programs enrolling patients in dose escalation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

FATE THERAPEUTICS INC reported second quarter ended June 30, 2023 results: revenue $0.9 million.

Period: second quarter ended June 30, 2023
Revenue: $0.9 million
Result: reported results

Exact text from the filing

June 30, 2023 were $385.2 million. In addition, as of June 30, 2023, cash receivables from the Company’s collaboration with ONO were $2.8 million. • Total Revenue: Revenue was $0.9 million for the second quarter of 2023, which was derived from the Company’s conduct of preclinical development activities for a second collaboration candidate targeting an undisclosed

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

FATE THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0000950170-23-039783

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.